Silas Inman

A prespecified subgroup analysis of the phase 3 lidERA trial showed an iDFS benefit with adjuvant giredestrant over SOC endocrine therapy in this population.

The B7-H4-directed ADC puxitatug samrotecan elicited responses in approximately half of patients with B7-H4-expressing recurrent or progressive endometrial cancer.

Seven-year follow-up from the CROWN trial has set a tall benchmark for the agents that followed it on the podium at the 2026 ASCO Annual Meeting in oncogene driven NSCLC.

LY4052031 demonstrated promising clinical activity after disease progression on enfortumab vedotin in metastatic urothelial carcinoma.

TERN-701 yielded a high response rate with deep molecular responses in patients with heavily pretreated chronic phase chronic myeloid leukemia.

The multimodal ICM+ model was prognostic for long-term recurrence following treatment in early breast cancer.

AZD0120 CAR T therapy shows rapid, deep responses and manageable safety in R/R myeloma, with ultra-fast manufacturing and strong early durability.

Early phase 3 data showed signals of efficacy with the addition of odronextamab to CHOP in patients with previously untreated DLBCL and high-risk features.

Rusfertide sustained hematocrit control and sharply reduced phlebotomy need through week 52 in PV, showing durable efficacy and a consistent safety profile.

Long-term data from the ALINA trail continued to support the use of adjuvant alectinib in resected, ALK-positive, early stage non–small cell lung cancer.

Pembrolizumab before and after surgery reduced the risk of death compared with placebo for patients with early-stage non–small cell lung cancer.

Capivasertib plus abiraterone acetate, prednisone, and androgen deprivation therapy was active in PTEN-deficient de novo metastatic HSPC.

NAPISTAR1-01 showed enduring benefit with TUB-040 in patients with platinum-resistant high-grade serous ovarian cancer.

Lenvatinib plus everolimus improved PFS vs cabozantinib in metastatic clear cell renal cell carcinoma after progression on a PD-1 inhibitor.

Giredestrant plus everolimus improved progression-free survival in ER-positive, HER2-negative advanced breast cancer after a prior CDK4/6 inhibitor.

Niraparib plus abiraterone acetate and prednisone improved rPFS vs abiraterone acetate and prednisone and placebo in patients with mCSPC with alterations in HRR genes.

Adjuvant pembrolizumab showed maintained OS and DFS vs placebo in patients with ccRCC at the 5-year analysis.

BCG plus mitomycin may represent good alternative to BCG alone in NMIBC.

Zilovertamab vedotin plus R-GemOx elicits responses in patients with relapsed or refractory diffuse large B-cell lymphoma.

Promising new agents are in development to address the unmet need resulting from resistance to endocrine therapy plus CDK4/6 inhibition in breast cancer.

Sara A. Hurvitz, MD, FACP, discusses the growing role of systemic therapy in HER2-positive breast cancer brain metastases.

Sonrotoclax plus zanubrutinib produced responses and was well tolerated in previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.

Isatuximab plus initial VRd and Rd maintenance demonstrated deep responses and MRD negativity in transplant-ineligible newly diagnosed multiple myeloma.

Patients with treatment naive DLBCL experienced high response rates when treated with zilovertamab vedotin plus R-CHP and a RP2D dose of the agent was selected.

Social determinants of health have a more pronounced effect on mortality among patients with AML who did not receive transplant vs those who did.

Pembrolizumab plus trastuzumab and chemotherapy reduced the risk of death by 20% in patients with advanced, unresectable, or metastatic HER2+ gastric or GEJ cancer.

The novel ALK inhibitor NVL-655 demonstrated encouraging activity in heavily pretreated patients with advanced ALK-positive NSCLC.

Dato-DXd did not significantly improve overall survival compared with docetaxel for patients with non–small cell lung cancer.

An exploratory analysis from the TROPION-Lung 01 study shows that positivity for TROP2 normalized membrane ratio can be predictive for improved efficacy in patients with non–small cell lung cancer treated with datopotamab deruxtecan.

Belantamab mafodotin plus bortezomib and dexamethasone improved median progression-free survival vs daratumumab plus bortezomib and dexamethasone in relapsed/refractory multiple myeloma.